Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma
Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma
复制标题
DOI：
10.1016/s0360-3016(97)00284-8
复制
发表时间：
1997-08-01
影响因子：
7
通讯作者：
Phillips, TL
中科院分区：
文献类型：
--
作者：
Le, QTX;Fu, KK;Phillips, TL
目的：评估分数大小、总时间、总剂量和其他预后因素对TI和T2声门癌局部控制的影响。方法和材料：1956年至1995年间，连续398例早期声门癌患者（315例T1和83例T2）在加州大学弗朗西斯科分校和相关机构接受了每天一次的确定性放疗。每周5天进行治疗。最小肿瘤剂量范围为46.6至77.6戈伊（中位数：63戈伊）。分割尺寸为43天;分割尺寸大于或等于2.25戈伊为100%，分割尺寸65戈伊为44%，总剂量小于或等于65戈伊为60%;脊髓活动度正常为79%，脊髓活动度受损为45%，声门下延伸病变为58%，无声门下延伸病变为77%。整个组的严重并发症发生率较低：1.8%。结论：总剂量、分次大小和总时间是T2声门癌局部控制的重要因素，而不是TI声门癌。前连合受累与TI局部控制降低相关，但与T2病变无关。对于T1病变，局部控制在治疗期间有所改善。对于T2病变，局部控制随着脊髓活动度和声门下伸展受损而降低。(C)1997年爱思唯尔科学公司
Purpose: To evaluate the influence of fraction size, overall time, total dose, and other prognostic factors on local control of TI and T2 glottic carcinomas.Methods and Materials: Between 1956 and 1995, 398 consecutive patients with early glottic carcinoma (315 T1 and 83 T2) were treated with once-a-day definitive radiotherapy at the University of California, San Francisco, and associated institutions. Treatment was delivered 5 days per week. Minimum tumor dose ranged from 46.6 to 77.6 Gy (median: 63 Gy). The fraction size was 43 days; 100% for fraction size greater than or equal to 2.25 Gy vs. 44% for fraction size 65 Gy vs. 60% for total dose less than or equal to 65 Gy; 79% for normal cord mobility vs. 45% for impaired cord mobility, and 58% for lesions with subglottic extension vs. 77% for those,without. The severe complication rate for the entire group was low: 1.8%.Conclusions: Total dose, fraction size, and overall time were significant factors for local control of T2 but not TI glottic carcinomas. Anterior commissure involvement was associated with decreased local control for TI but not T2 lesions. For T1 lesions, local control improved over the treatment era. For T2 lesions, local control decreased with impaired cord mobility and subglottic extension. (C) 1997 Elsevier Science Inc.